Across TCGA pan-cancer cohorts, RNU6ATAC10P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RNU6ATAC10P’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNU6ATAC10P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6ATAC10P is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.
KIRC and LUSC are the cancer types where RNU6ATAC10P tumor–normal differential expression is most reproducible.